Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): Report of a phase I/II trial

Annals of Hematology

Volumn 93, Issue 3, 2014, Pages 459-462

  Hopfinger, Georg ^a   Nösslinger, Thomas ^b   Lang, Alois ^c   Linkesch, Werner ^d   Melchardt, Thomas ^a   Weiss, Lukas ^a   Egle, Alexander ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c LKH   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Lenalidomide; Peripheral T cell lymphoma; PTCL; Vorinostat

Indexed keywords

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SURVIVAL ANALYSIS; THALIDOMIDE; THROMBOCYTOPENIA;

EID: 84894315828     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2009-0     Document Type: Article

References (13)

1. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol Off J Am Soc Clin Oncol. doi: 10.1200/jco.2012.44.7524
2. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol Off J Eur Soc Med Oncol/ESMO 1(1):45-50
3. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827-5834. doi: 10.1182/blood-2010-10-312603
4. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-39. doi: 10.1182/blood-2006-06-025999
5. Beckers MM, Huls G (2013) Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. Eur J Haematol 90(2):162-163. doi: 10.1111/ejh.12053
6. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116(19):4541-4548. doi: 10.1002/cncr.25377
7. Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, Derenzini E, Pileri S, Baccarani M (2011) Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 52(8):1585-1588. doi: 10.3109/10428194.2011.573031
8. Swerdlow SH; Campo E; HN, et al.eds. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC
9. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid(R)) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer (Oxford, England: 1990). doi: 10.1016/j.ejca.2013.04.029
10. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 25(21):3109-3115. doi: 10.1200/jco.2006.10.2434
11. Uike N, Ogura M, Imaizumi Y, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Shiota T, Tobinai K (2012) Multicenter phase I dose-escalation study of lenalidomide in patients with relapsed adult T-cell leukemia-lymphoma (ATL) or peripheral t-cell lymphoma (PTCL). ASH Annu Meet Abstr 120(21):2737
12. Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson DM Jr, Greenfield CN, Sell M, Devine SM (2012) Phase I trial of lenalidomide + vorinostat after autologous transplant in multiple myeloma. ASH Ann Meet Abstr 120(21):3114
13. Richter JR, Bilotti E, McBride L, Schmidt L, Gao Z, Tufail M, Anand P, McNeill A, Bednarz U, Graef T, Vesole DH, Siegel DS (2011) Salvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/dexamethasone relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 118(21):3986